Downregulation of AGR2, p21, and cyclin D and alterations in p53 function were associated with tumor progression and chemotherapy resistance in epithelial ovarian carcinoma

Mariana Rezende Alves¹ | Natalia Cruz e Melo² | Mateus Camargo Barros-Filho¹ |
Nayra Soares do Amaral¹ | Felipe Ilelis de Barros Silva¹ | Glauco Baiocchi Neto³ |
Fernando Augusto Soares⁴ | Louise de Brot Andrade⁴ | Rafael Malagoli Rocha²

¹International Research Center, AC Camargo Cancer Center, São Paulo, Brazil
²Molecular Gynecology Laboratory, Gynecologic Department, Federal University of São Paulo, São Paulo, Brazil
³Department of Gynecology Oncology, AC Camargo Cancer Center, São Paulo, Brazil
⁴Department of Anatomic Pathology, A.C. Camargo Cancer Center, São Paulo, Brazil

Correspondence
Mariana Rezende Alves, International Research Center, AC Camargo Cancer Center, São Paulo, Brazil.
Email: mariana.rezendealves@gmail.com

Funding information
Coordination for the Improvement of Higher Educational Personnel (CAPES); Poundbury Cancer Institute

Abstract
Anterior gradient 2 protein belongs to a family of chaperone-like proteins, namely protein disulfide isomerase. Generally, AGR2 is highly expressed in mucus-secreting cells and endocrine organs, and in this study, we aimed to evaluate AGR2 and cell cycle molecules in epithelial ovarian cancer and its implications on prognosis. One hundred seventy-five patient’s samples that were diagnosed with primary epithelial ovarian carcinoma were selected. All the patients were treated with platinum-taxane standard chemotherapy after surgery and CA125 serum levels were routinely determined. Four-micrometer-thick sections were processed by immunohistochemistry using an automated immunostainer, Ventana BenchMark AutoStainer with AGR2, cyclin D1, p21WAF1, and p53. Forty-nine of 167 cases (29.3%) showed strong to moderate cytoplasmic marking of AGR2, and 118 (70.7%) had weak to negative expression. The absence of the AGR2 protein was observed in high-grade serous carcinoma (P < .001) and significantly associated with disease-free survival (DFS; P = .034). The expression of G1-S phase-regulatory proteins showed loss of p21 in high-grade serous carcinoma (P < .001) and was related with poor DFS (P = .003). Strong and diffuse immunoexpression of p53 plus complete absence of p53 staining was interpreted as likely indicating a TP53 gene mutation. This result showed worse DFS alone (P = .012) and combined with low levels of AGR2 (P = .005). The expression profile of AGR2 and cell cycle proteins here presented was showed as good prognosis marker in epithelial ovarian cancer. This finding suggests AGR2 and as putative biomarker of disease progression in chemotherapy-treated high-grade serous carcinoma patients.

Keywords
AGR2, cell cycle, epithelial ovarian cancer, IHC, prognosis
1 INTRODUCTION

Ovarian cancer is one of the deadliest gynecological malignancies worldwide with 22,280 new cases and 14,240 estimated deaths in the United States. Historically, treatment has involved surgery combined with platinum-based chemotherapy. The main factors affecting patient’s prognosis are advanced stage at diagnosis and primary or secondary chemotherapy drug resistance, especially for that persistent or recurrent ovarian carcinoma. The TP53 gene, encoding the p53 tumor suppressor, is the most frequent target for mutation in human cancer. Of the currently known molecular alterations in ovarian carcinoma, loss of p53 function is the most common one, and some studies describe AGR2 (anterior gradient 2 protein) inhibits p53 activity.

AGR2 is a small 154 amino acid protein with a single central Cys residue, which belongs to a family of chaperone-like proteins, namely protein disulfide isomerase (PDI). PDI-related proteins are microenvironmentally regulated proteins that can catalyze the formation, reduction, or isomerization of disulfide bonds in their network. These enzymatic reactions facilitate protein maturation into bioactive conformation in the endoplasmic reticulum (ER). Generally, AGR2 is highly expressed in mucus-secreting cells and endocrine organs, such as lung, stomach, colon, prostate, and small intestine, from an evolutionary perspective, believed to be involved in the epithelial barrier function especially on AGR2 losses, which elevates ER stress in some of the intestine cell types, providing the first evidence for AGR2 function in ER-dependent protein folding.

In tumorigenesis, AGR2 plays an important role by activating survival and metastasis pathways by interacting with cyclin D1, cathepsin B, D, Myc, p-Src, and EGFR and by blocking cell death inhibiting p53 function. The overexpression of AGR2 was observed in several tumor types, which supports the hypothesis of AGR2 being an oncogene, but the downregulation of this gene also was observed in prostate tumors, ovarian, colorectal, and pancreas.

Despite the existing knowledge that AGR2 may interact with p53, little is known about its possible relation with cell cycles proteins and prognostic value in ovarian cancer context. In order to evaluate the association of AGR2 and cell cycle molecules in ovarian cancer and its implications on prognosis, we have used immunohistochemistry to investigate protein expression of AGR2, p21, cyclin D, and p53. Our study showed that the downregulation profile of AGR2, p21, and cyclin D, and alterations of p53 function were associated with tumor aggressiveness characteristics such as progression, invasion, relapse, and worse disease-free survival.

2 MATERIALS AND METHODS

2.1 Clinical samples

One hundred seventy-five samples from patients diagnosed with primary epithelial ovarian carcinoma between 2003 and 2013 were selected from the Anatomic Pathology Department of AC Camargo Cancer Center (São Paulo, Brazil). All patients provided written informed consent for the collection of samples and subsequent analysis, and this study was approved by the Ethics Committee of the institution. Patients were treated with platinum-taxane standard chemotherapy after surgery and CA125 serum levels were routinely determined to evaluate response. Staging of the disease was assessed according to FIGO criteria, optimal debulking surgery was defined as less than 1 cm of gross residual disease, and suboptimal debulking surgery was defined as more than 1 cm of residual disease.

Recurrence was defined per GCIG criteria after evaluating RECIST and CA125 progression in the medical charts, and the date of the earlier event was considered for progression. CA125 progression by GCIG is considered if there is a doubling in CA125 from the upper limit of normal and for those patients whose CA125 never fell to the normal range, a doubling from the nadir is considered progression.

Disease-free survival (DFS) was calculated as the interval from primary surgery to disease progression or recurrence. Platinum-free interval (PFI) was considered the interval between the date of the last platinum compound infusion and the date of disease progression. Platinum-resistant recurrence was defined as recurrence with a PFI of <6 months. Overall survival was determined by the time interval between the date of diagnosis and the date of death due to ovarian cancer.

The clinical data obtained from the medical records included age at diagnosis, type of surgery, volume of residual disease after surgery (1 cm or >1 cm), tumor stage, date of last platinum-based chemotherapy, and date of recurrence after each treatment until last follow-up. The histologic characteristics of surgically resected specimens were reviewed by expert gynecopathologist (LBA) in order to confirm the histologic subtype. Pathological data, such as impairment of ovarian surface and fallopian tube, bilateral involvement, lymphatic and blood vascular invasion, and lymph node involvement, were evaluated. Histologic subtype was diagnosed based on most recent WHO classification of ovarian tumors. Formalin-fixed paraffin-embedded samples were used for the construction of a tissue microarray.

2.2 IHC analysis

Representative tumor areas were marked on HE-stained slides by the pathologist, and two tissue cores (diameter...
1 mm) subsequently punched out the respective donor paraffin blocks using a tissue microarray. Four-micrometer-thick sections were processed by immunohistochemistry using an automated immunostainer (Ventana BenchMark AutoStainer) with polyclonal anti-human AGR2 antibody (1:100 ABGENT) and monoclonal antibody: Cyclin D1 rabbit (clone EP12; ready to use A. MENARINI), p21WAF1 (clone DCS-60.2; ready to use A. MENARINI), and p53 mouse anti-human antibody DO-7 (dilution 1:100; Dako), suitable for detecting both wild-type and mutant p53 protein, were used as the primary antibody. The antibodies were incubated at 37°C for 32 minutes. Specific staining was detected by applying an enzyme (with a corresponding substrate-chromogen system—HRP) directly conjugated to the secondary antibody. The complex was then visualized with hydrogen peroxide substrate and 3, 3′- diaminobenzidine tetrahydrochloride (DAB) chromogen, counterstained with hematoxylin, and mounted for microscopic examination. All batches included positive controls, and omission of primary antibody was used as negative control.

Scores are expressed as a percentage of positive nuclear staining within representative areas of the tumor sample. Cyclin D1 and p21 expression, analyzed in 162 and 158 respectively according to tissue availability of interpretation, were scored by percentage of positive cells, as follows: 0 (absence positive cells or until 10% of positive cells), 1 (11%-49% of positive cells, irregular stain), and 2 (≥50% of positive cells, diffuse stain). The categories 0 was categorized as low level and 2 and 3 were considered as high level of staining. p53 expression had 166 conclusive samples able to perform the analysis, which positive staining was defined as a homogeneous pattern of strong and diffuse nuclear staining. The absence of staining was considered negative, and patchy patterns of nuclear staining interspersed with negative staining were considered p53 on basal levels. To AGR2 evaluation it was performed in 167 tissue samples, and the percentage of positive cytoplasmic tumor cells it was scored as established by the percentage of positive cells (PPC) and intensity of immunostaining (II) [(HSCORE = (PPC × II), varied from 0% to 100%, and intensity of immunostaining (II), varied from 0 (negative staining), 1 (weak staining), 2 (moderate staining), and 3 (strong staining), in which [HSCORE = (PPC × II), with a ranking between 0 and 300]. Low levels of AGR2 were categorized as 0 to 100 and high levels as 101 to 300.

2.3 | Public available databases

To integrate the data obtained by IHC, we analyzed the expression of AGR2, p53, p21, and cyclin D1 in public available databases: (1) proteome data from RPPA (reverse phase protein array) for TP53 (p53), CDKN1A (p21), and CCND1 (cyclin D1), obtained from TCGA ovarian carcinoma patients, downloaded from cBioPortal (http://www.cbiopiortal.org/); (2) mass spectrometry data from Ovarian Serous Cystadenocarcinoma cancer downloaded from Clinical Proteomic Tumor Analysis Consortium (CPTAC; https://cptac-data-portal.georgetown.edu/cptacPublic/), available only for AGR2 and TP53, and 3—exome sequencing data of TP53 (somatic gene-level nonsilent mutation) from TCGA ovarian carcinoma patients, downloaded from cBioPortal. All the remained details are available on supplementary data (Appendix S1).

2.4 | Statistical analysis

The database was generated in SPSS, version 21.0. The association between categorical variables was analyzed by Chi-square or Fischer’s exact test. Survival curves were determined by Kaplan-Meier method, and the comparison of survival curves for each variable category was performed using log-rank test. A univariate analysis was performed by Cox regression. For all tests, P ≤ .05 was considered statistically significant.

3 | RESULTS

3.1 | Sample characteristics

We evaluated 175 ovarian cancer samples with a median age of 56 years (minimum of 17 years and maximum of 83 years old). According to histologic classification, serous tumors was the most frequent subtype, n = 126 (71.9%). One hundred thirty-two (77.2%) patients were diagnosed in advanced stages of the disease (III-IV) and 124 (71%) of the patients had recurrence of the disease, which 44 (28.2%) patients had platinum-free interval less than 6 months. The remaining clinicopathological features of all 175 patients are described in Table 1.

3.2 | AGR2 expression is associated with less aggressive tumors and best prognosis

One hundred sixty-seven samples were analyzed for this marker that showed a strictly cytoplasmic staining (Figure 1). Forty-nine of 167 cases (29.3%) showed strong to moderate cytoplasmic marking of AGR2 and 118 (70.7%) had weak to negative expression. The absence of the AGR2 protein was observed differentially expressed in high-grade serous carcinoma (<0.001), samples with lymphatic vascular invasion (P = 0.003), bilateral involvement (P = 0.005) necrosis (P = 0.034), ovarian surface involvement (P = 0.032), and lymph node metastasis (P = 0.003). Regarding the response to treatment, the absence of the protein corresponded to 75.9% of patients that relapsed (P = .049; Table 2).

Kaplan-Meier curves showed the importance of AGR2 expression in patients’ outcome. The median of DFS for patients whose tumors presented positivity for AGR2 was 44 months, which was significantly higher than the median survival of patients whose tumors lacked AGR2 expression,
which was 22 months \( (P = .034; \text{Figure S1}) \). OS showed no difference between the curves \( (P = .227; \text{Table 3}) \). A Cox proportional hazards regression model showed that the absence of AGR2 protein expression in the tumor was a strong predictor of poor DFS \( \text{HR: 0.631; 95\% confidence interval: 0.412-0.966; } P = .034; \text{Table 4}) \).

### 3.3 Expression of G1-S phase-regulatory proteins and the association with clinicopathological parameters

The expression of G1-S phase-regulatory proteins was analyzed using cyclin D1, p21WAF1/Cip, and p53 proteins. Cyclin D1 was analyzed in 162 cases and the majority of cases showed a nuclear staining, but interestingly 27 (16.7\%) of the samples showed nuclear and cytoplasmic staining. Weak cyclin D1 staining was observed in high-grade serous carcinoma \( (P < .001) \), lymphatic vascular invasion \( (P = .026) \), bilateral involvement \( (P < .001) \), necrosis \( (P = .004) \), and patients with recurrence \( (P = .006) \).

p21 had a specific, sharp, and well-localized nuclear and cytoplasmic staining pattern, strongly staining in 35 (22.2\%) of the 158 cases analyzed. Loss of p21 was significant in high-grade serous carcinoma \( (P < .001) \), lymphatic vascular invasion \( (P = .003) \), bilateral involvement \( (P = .001) \), necrosis \( (P = .002) \), ovarian surface involvement \( (P = .006) \), lymph node metastasis \( (P = .015) \), stage \( (P < .001) \), death \( (0.004) \), and patients with recurrence \( (P = .006) \).

p53 expression was evaluated in 166 samples where 67 of 166 (40.4\%) presented strong and diffuse marking. 45 of the 166 samples had patchy patterns of nuclear staining, and 54 of 166 (32.5\%) presented negative staining. It is already established that the DO-7 clone p53 surrogates a mutational status in the diagnostic workup of ovarian carcinomas.\(^{27}\) Strong and diffuse immunexpression of p53 plus complete absence of p53 staining is generally interpreted as likely indicating a TP53 gene mutation.\(^{24,28}\) We grouped the results of the protein analysis according to their mutational status and correlate them with clinicopathological features. We observed that p53 is present in 101 of 166 (83.5\%) of the high-grade serous carcinoma samples and 20 of 53 (16.5\%) in other histology \( (P < .001) \). p53 staining based on its mutational status was observed differentially expressed in high-grade serous carcinoma \( (P < .001) \), lymphatic vascular invasion \( (P = .008) \), bilateral involvement \( (P < .001) \), necrosis \( (P < .001) \), ovarian surface involvement \( (P = .001) \), stage \( (P = .001) \), death \( (P = .045) \), and recurrence \( (P = .022) \).

Regarding Kaplan-Meier analysis, lower levels of cyclin D1 showed a median of DFS of 23 months; however, it did not show difference on survival curves \( (P = .135) \) and overall survival \( (P = .601) \). p21 survival curves showed a difference between lower levels of staining and DFS \( (P = .003) \) and a marginal significance on OS \( (P = .071) \). Using a classification as aberrant (excessive or completely negative) and basal levels, p53 expression showed a significant prognostic factor for DFS in our group of patients \( (P = .012) \) but no difference on OS \( (P = .176; \text{Figure S1}) \). Univariate Cox regression analysis showed that the lower levels of p21 protein expression in the tumor were a strong predictor of OS survival \( (HR: 0.473; 95\% confidence interval: 0.236-0.950; P = .035) \) and DFS \( (HR: 0.423; 95\% confidence interval: 0.241-0.741; P = .003) \). The remained protein values of Cox proportion hazards model are summarized in Table 4.
3.4 | Association of AGR2 and G1-S phase-regulatory proteins

The Chi-square test for independence was used to discover whether there is an association between AGR2 and the cell cycle proteins. It is shown in Table 5 that the strength of association between AGR2 and cyclin D1, and p21 and p53 is strong. Taking these results together, we tested the pattern of expression of AGR2 low levels with cyclin D1 low levels, p21 low levels, and p53 alterations, respectively, on survival analysis. Each pattern of expression was calculated separately according to DFS (Figure 2) and $\text{AGR2}^{\text{low}}/\text{cyclin} \ D1^{\text{low}}$ showed a certain trend toward significance on the survival curves ($P = .081$) DFS analysis; $\text{AGR2}^{\text{low}}/\text{p21}^{\text{low}}$ presented a marginal trend toward significance ($P = .054$); and $\text{AGR2}^{\text{low}}/\text{p53}^{\text{aberrant}}$ a strong difference between the curves ($P = .005$) on DFS.

3.5 | Protein analysis of public data

A publically available data set was used to examine AGR2, cyclin D1, p21, and p53 protein expression in human ovarian cancer. The data set was generated using three platforms, and these analyses were not able to confirm our findings. However, AGR2 overall survival, by mass spectrometry analysis, showed a significantly higher survival rates (58.3%) compared with patients whose tumors lacked AGR2 expression (40.2%; $P = .0309$; Figure 3). The additional 213 cases
| Variables                      | AGR2 | p53 | p21 | Cyclin D1 |
|-------------------------------|------|-----|-----|-----------|
|                               | n (%)| n (%)| n (%)| n (%)     |
| **Histology**                 |      |      |      |           |
| HGSOC                         | 95 (80.5) | 12 (26.7) | 101 (83.5) | 95 (77.2) | 101 (74.8) |
| Others                        | 23 (19.5) | 33 (73.3) | 20 (16.5) | 28 (22.8) | 35 (25.2) |
| **Lymphatic vascular invasion**|      |      |      |           |
| No                            | 28 (38.9) | 22 (71) | 32 (40.5) | 31 (38.8) | 39 (44.3) |
| Yes                           | 44 (61.1) | 9 (29) | 47 (59.5) | 49 (61.3) | 49 (55.7) |
| **Blood vascular invasion**   |      |      |      |           |
| No                            | 58 (80.6) | 30 (96.8) | 65 (82.3) | 69 (86.3) | 75 (85.2) |
| Yes                           | 14 (19.4) | 1 (3.2) | 14 (17.7) | 11 (13.8) | 13 (14.8) |
| **Bilateral involvement**     |      |      |      |           |
| No                            | 22 (31.9) | 8 (26.7) | 54 (69.2) | 53 (68.8) | 56 (65.9) |
| Yes                           | 47 (68.1) | 16 (39) | 5 (12.5) | 35 (55.7) | 57 (44.3) |
| **Necrosis**                  |      |      |      |           |
| Absence                       | 36 (40.9) | 27 (73) | 34 (35.8) | 36 (37.5) | 44 (41.1) |
| Presence                      | 52 (59.1) | 10 (27) | 61 (64.2) | 60 (52.5) | 63 (58.9) |
| **Impairment of ovarian surface** |      |      |      |           |
| No                            | 11 (16.7) | 13 (46.4) | 10 (13.9) | 12 (16) | 15 (18.8) |
| Yes                           | 55 (83.3) | 53 (53.6) | 62 (86.1) | 63 (53.6) | 35 (81.3) |
| **Metastatic lymph node**     |      |      |      |           |
| No                            | 11 (16.7) | 19 (59.4) | 37 (51.4) | 35 (46.7) | 45 (52.9) |
| Yes                           | 55 (83.3) | 3 (40.6) | 35 (48.6) | 40 (53.3) | 40 (47.1) |
| **Surgery**                   |      |      |      |           |
| Primary debulking surgery     | 84 (72.4) | 38 (84.4) | 87 (73.1) | 90 (74.5) | 100 (75.2) |
| Interval debulking surgery    | 32 (27.6) | 7 (15.7) | 32 (26.9) | 31 (25.6) | 33 (24.8) |
| **Residual disease**          |      |      |      |           |
| <1 cm                         | 71 (68.3) | 32 (80) | 72 (67.9) | 69 (65.7) | 85 (71.4) |
| >1 cm                         | 33 (31.7) | 8 (20) | 34 (32.1) | 36 (34.3) | 34 (28.6) |
| **Stage**                     |      |      |      |           |
| I/II                          | 17 (14.9) | 18 (40.9) | 18 (15.3) | 18 (15.1) | 27 (20.6) |
| III/IV                        | 97 (85.1) | 26 (59.1) | 100 (84.7) | 101 (84.9) | 104 (79.4) |
| **ECOG**                      |      |      |      |           |
| 0                             | 42 (45.2) | 22 (59.5) | 45 (46.9) | 42 (43.8) | 55 (50.9) |
| 1.2.3                         | 51 (54.8) | 15 (40.5) | 51 (53.1) | 54 (56.3) | 53 (49.1) |
| **Chemotherapy**              |      |      |      |           |
| Neoadjuvant                   | 79 (75.2) | 28 (77.8) | 83 (76.1) | 86 (78.9) | 93 (77.5) |
| Adjuvant                      | 26 (24.8) | 8 (22.2) | 26 (23.9) | 23 (21.1) | 27 (22.5) |
| **Death**                     |      |      |      |           |
| No                            | 57 (48.3) | 28 (77.8) | 83 (76.1) | 86 (78.9) | 93 (77.5) |
| Yes                           | 61 (51.7) | 16 (35.6) | 66 (54.5) | 68 (55.3) | 62 (45.9) |

(Continues)
of p53 exome sequencing were performed to support the IHC evaluation. The results showed a predominant p53 mutant in the ovarian cancer cases (n = 188), but its values did not provide any information on survival analysis (Appendix S1).

4 DISCUSSION

The increase in AGR2 has been associated with phenotypes such as cell viability, invasion, and metastasis in various human cancers, however, in our study, the expression of AGR2 evaluated by IHC was associated with better prognosis, suggesting a versatility in the function of this protein in cancer pathophysiology. Here, we observed that the lower levels of AGR2 protein in ovarian carcinoma were correlated with high-grade serous carcinoma and characteristics of malignancy, such as lymphatic vascular invasion, bilateral involvement, necrosis, ovarian surface involvement, lymph node metastasis, and relapse (Table 2). We found an association between histology (P < .001; Figure 1), which corroborates with Ames and colleagues, who observed a greater expression of AGR2 in endometrioid and mucinous subtypes when compared to the high-grade serous carcinoma, and absence of AGR2 was associated with increased malignancy, tumor progression, and relapse.

The functional role of increasing AGR2 in promotion oncogenesis has been established by the activation of survival pathways and metastasis, but little is known about how the reduction in AGR2 would act facilitating tumor progression. Some functional studies show the importance of AGR2 in cell differentiation and suggest that low levels of AGR2 promote reduction in protein adhesion expression and increases resistance to apoptosis, which could justify the aggressive phenotype of our results, which allows the ovarian carcinoma cell to establish an outpost on the omentum and peritoneum.

In an elegant review, Chevet and colleagues described AGR2 biological pathways, which AGR2 is presented in mechanism as a mediator of tamoxifen drug resistance in human breast cancer in esophageal cancer progression, and stimulating key cancer-signaling pathways, such as cyclin D1, metastasis, and others. In esophageal metaplasia tissue, Pohler and colleagues identified a novel p53 inhibitors—AGR2, which was validated as a potent inhibitor of p53-dependent transcription and a growth-promoting proto-oncogene. In our results, p53 analysis, called as p53 aberration, was observed in 121 samples (72.9%) in which, 101 was classified as high-grade serous carcinoma, the most frequent subtype in our casuistic (n = 114; Table 2).

Sequencing of DNA tumor is the gold standard to detect different types of p53 mutation and relate these to clinical outcome. Determining the true prevalence of TP53 mutation is critical for understanding the pathogenesis of ovarian tumor, especially...
high-grade serous carcinoma.\textsuperscript{5,6} The rationale behind this interpretation of immunohistochemistry is that inframe point mutations of p53 alter the conformation of the protein and prolong its biological half-life, thus intensifying the immunohistochemical staining result. Other mechanisms that abolish activity (eg, homozygous deletion of the gene or truncating mutations) may result in loss of p53 protein and are identified as the absence of staining using sensitive immunohistochemical assay.

An independent test showed that the levels of AGR2 differ from the presence of aberrant p53 (Table 5). Survival curves (Figure 2) also could illustrate this hypothesis, showing that low levels of AGR2 together with p53 aberrant show worse DFS ($P = .005$). The ability of AGR2 to suppress p53 activity could be explained, in part, in an environment or tumor which is lower frequency of p53 mutations, for example breast cancer,\textsuperscript{33,34} a disease where AGR2 is overexpressed and p53 wild-type is maintained in a majority of cases.\textsuperscript{8,35,36} Conversely, where p53 has a high frequency of mutation, as ovarian cancer,\textsuperscript{5,6} the suppression of p53 from AGR2 pathway may be less active.\textsuperscript{7,39}

### Table 3: Univariate log-rank test of protein for overall survival and disease-free survival rate in 5 years

| Features | Overall survival | | | Disease-free survival | | |
|----------|------------------|------------------|------------------|------------------|------------------|
|          | Number of patients | Survival rates (%) | $P$-value | Number of patients | Survival rates (%) | $P$-value |
| AGR2     | High  | 49  | 32 (65.3) | .227 | 49  | 22 (44.9) | .034* |
|          | Low   | 118 | 32 (65.3) | .601 | 114 | 29 (25.4) | .135 |
| Cyclin D1| High  | 27  | 15 (55.6) | .072 | 27  | 14 (51.9) | .003* |
|          | Low   | 135 | 76 (56.3) | .176 | 131 | 33 (25.2) | .012* |
| p21      | High  | 35  | 26 (74.3) | .035* | 35  | 21 (60) | .003* |
|          | Low   | 123 | 65 (52.8) | .473 (0.236-950) | 119 | 28 (23.5) | .029* |
| p53      | Basal | 45  | 30 (66.7) | .176 | 44  | 21 (47.7) | .012* |
|          | Alteration | 121 | 64 (52.9) | |

*Bold values: statistically significance ($P \leq 0.05$) calculated by log-rank test.

### Table 4: Univariate Cox regression analysis for overall survival and disease-free survival

| Feature | Overall survival | Disease-free survival |
|---------|------------------|-----------------------|
| AGR2    | HR (95% CI)      | $P$-value             |
| High    | 1                | 1                     |
| Low     | 0.810 (0.497-1.321) | .399                 |
|         | 0.631 (0.412-0.966) | .034*                |
| Cyclin D1 | High | 1                | 1                     |
| Low     | 1.118 (0.617-2.027) | .712                 |
| p21     | High | 1                | 1                     |
| Low     | .473 (0.236-950) | .035*                |
| p53     | Basal | 1                | 1                     |
| Alteration | 1.609 (0.931-2.779) | .088                 |
|         | 1.626 (1.050-2.517) | .029*                |

*Bold values: statistically significance ($P \leq 0.05$) calculated by Cox regression model. CI, confidence interval; HR, hazard ratio.

### Table 5: Association of AGR2 expression and cell cycle proteins

| Variables | Category | n (%) | | |
|-----------|----------|-------|-------|-------|
|           |          | Absence | Presence | $P$-value |
| Cyclin D1 | No       | 101 (87.1) | 31 (72.1) | .046* |
|           | Yes      | 15 (12.9) | 12 (27.9) | |
| p21       | No       | 94 (85.5) | 27 (58.7) | .001* |
|           | Yes      | 16 (14.5) | 19 (41.3) | |
| p53       | Basal    | 24 (20.5) | 20 (45.5) | .003* |
| Alteration | 93 (79.5) | 24 (54.5) | |

*Bold values: statistically significance ($P \leq 0.05$) calculated by Chi-square or Fischer’s exact test.

The p53 pathway can negatively regulate the cell cycle through the activation of p21.\textsuperscript{37,38} As a proposed investigation of cell cycle molecules, reduction in p21 it was associated with high-grade serous carcinoma subtype, and anatomopathological characteristics of lymphatic vascular invasion, bilateral...
involvement, necrosis, ovarian surface involvement, tumor
stage, death, and relapse (Table 2 and Figure 2). Inactivation
of p53 function leads to loss of p21 induction and impair-
ment of cyclin/CDK complex inhibition. Indeed, we found
that downregulation of p21 was significantly associated with
poor survival and a shorter disease-free survival interval, as
previously demonstrated by others.39,40

Cyclin D1 is also positively regulated by AGR2, and
consequently, the reduction in AGR2 induces a decrease
in cyclin D1 expression.29,41 Cyclin D1 and its binding
partners CDK4/6 partially regulate the cell cycle by pro-
moting the G1 to S transition in the cell cycle.42 Normally,
it is observed overexpression of cyclin D1 in a variety of
human carcinomas 24,42 is correlated with aggressiveness of
the tumor and chemoresistance in ovarian, pancreatic, and
nonsmall-cell lung carcinoma.43,44 However, some studies
show the reduction in cyclin D1 may be an event interrelated
to tumor progression45 and the cisplatin resistance.46 In our
findings, weak cyclin D1 staining was associated with high-
grade serous carcinoma, lymphatic vascular invasion, bilat-
eral involvement, necrosis, and patients’ relapse (Table 2 and
Figure 2). Shi and colleagues also observed lower expression
of cyclin D1 in serous carcinoma compared with mucinous
and clear cell carcinoma subtypes. In addition, functional
studies observed that the silencing of the cyclin D1 gene in-
creased migration in breast cancer cells, and cancers with low

**FIGURE 2** Kaplan-Meier curve for disease-free survival for A, AGR2 low and high levels; B, comparison of protein expression levels
between AGR2low/p53aberrant, C, AGR2low/p21low, and D, AGR2low/cyclin D1low. All P-values calculated by the log-rank test.
expression presented were highly infiltrative and presented low recurrence-free survival, suggesting that cyclin D1 has other functions distinct from the proliferation process.45

Nevertheless, original studies of AGR2 show that this protein has an important function in the preservation of cellular homeostasis, by promoting the differentiation of secretory epithelial cells.47 Downregulation of AGR2 seems to be related to tumor progression of tumors originating in secretory organs.15,18-21 Thus, hypothetically, in the early stage of the tumor, increased AGR2 expression could activate proliferative mechanisms, such as increased cyclin D1, but with tumor progression, the reduction in AGR2 could activate mechanisms of invasion and metastasis by reducing adhesion molecules.21,31 Loss of AGR2 and cyclin D1 expression during ovarian tumor progression suggests that signaling pathways are altered during the early and advanced stages of the disease and that disbalance in the expression of AGR2 may contribute to the tumor phenotype (Figure 4). To test this hypothesis, functional studies are needed to elucidate the role of AGR2 in carcinogenesis and tumor progression.

Besides this mechanism, it was shown that the expression of AGR2 is positively related to the expression of epithelial markers, and that the reduction in AGR2 induced by TGF-β created features of mesenchymal cells such as the loss of E-cadherin, and induction of N-cadherin. This study showed the importance of AGR2 in maintaining of epithelial phenotypes and suggested that the role of AGR2 in epithelial-mesenchymal transition is dependent on its localization.48 The secreted AGR2 was associated with the extracellular and can influence the activities of multiple extracellular signaling of VEGF and FGF2.49

To support our data, we integrate the data obtained by analyzing the protein expression of AGR2 and the other cell cycle protein analysed (p53, p21, and cyclin D1) in public available database. In this approach, we confirmed the lower expression of AGR2 protein as a marker of poor prognosis in epithelial ovarian carcinoma (shorter overall survival). Conversely, p53 mutation and p21 and cyclin D1 protein expression lacked an association with the overall and disease-free survival. This observation can be probably due to differences in the methodology adopted by our study (IHQ) and TCGA/CPTAC (RPPA and mass spectrometry) and disparities between the cohorts.

**Figure 3** Kaplan-Meier curve for AGR2 overall survival by mass spectrometry analysis from Clinical Proteomic Tumor Analysis Consortium (CPTAC)

**Figure 4** Hypothetic model of AGR2 and cyclin D1 in the progression of ovarian cancer. In early stage of ovarian cancer, increase in AGR2 expression could activate mechanisms of proliferation, such as increase in cyclin D1. In advanced stage, the reduction in AGR2 could activate mechanisms of invasion and metastasis, by reducing adhesion molecules. The metastatic process occurs preferentially to the peritoneal cavity (I) and lymph nodes (II); however, in late stages, the hematogenous metastasis may also occur (III)
Our study observed that the downregulation profile of AGR2, p21, and cyclin D1 and the presence of the suggestive p53 mutation were associated with tumor progression and relapse (Table 2 and Figure 2). Currently, the main factors affecting the prognosis and high mortality of patients with ovarian cancer are advanced stage at diagnosis and primary or secondary chemotherapy drug resistance.48–50 Thus, the development of more accurate and earlier detection tests for this disease is undoubtedly the number one priority for achieving long-term reduction in mortality from ovarian cancer, and our results show that the protein evaluation of AGR2, p21, and cyclin D and the suggestive mutation in p53 can differentiate advanced staging and tumor recurrence in response to treatment with carboplatin.

In conclusion, our study observed that the downregulation of AGR2, p21, and cyclin D1 and the presence of the suggestive p53 mutation were associated with tumor aggressiveness characteristics such as progression, invasion, death, relapse, and worse DFS. Interestingly, the expression profiles of the proteins presented herein could predict tumor recurrence after treatment with carboplatin. Currently, relapse in ovarian cancer presents one of the most important limitations in the survival gains of patients, so the evaluation of AGR2 and the proteins of the cell cycle can assistance in the identification of these patients.

ACKNOWLEDGMENTS

This study was supported by Coordination for the Improvement of Higher Educational Personnel (CAPES) and Poundbury Cancer Institute. We are very grateful for their valuable technical assistance on protein analysis.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ORCID

Mariana Rezende Alves http://orcid.org/0000-0001-5904-4890

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30.
3. Kajiyama H, Shibata K, Mizuno M, et al. Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma. Int J Gynecol Cancer. 2012;22:801-806.
4. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
5. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433-43.
6. Kurman RJ, Shih IeM. Molecular pathogenesis and extracellular origin of epithelial ovarian cancer—shifting the paradigm. Hum Pathol. 2011;42:918-31.
7. Pohler E, Craig AL, Cotton J, et al. The Barrett’s antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol Cell Proteomics. 2004;3:534-547.
8. Hrstka R, Bouchalova P, Michalova E, et al. AGR2 oncprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway. Mol Oncol. 2016;10:652-662.
9. Bergström JH, Berg KA, Rodríguez-Piñeiro AM, Stecher B, Johansson ME, Hansson GC. AGR2, an endoplasmic reticulum protein, is secreted into the gastrointestinal mucus. PLoS ONE. 2014;9:e104186.
10. Sevier CS, Kaiser CA. Formation and transfer of disulphide bonds in living cells. Nat Rev Mol Cell Biol. 2002;3:836-847.
11. Brychtova V, Vojtesek B, Hrstka R. Anterior gradient 2: a novel player in tumor cell biology. Cancer Lett. 2011;304:1-7.
12. Persson S, Rosenquist M, Knoblaich B, Khosravi-Far R, Sommerin M, Michalak M. Diversity of the protein disulfide isomerase family: identification of breast tumor induced Hag2 and Hag3 as novel members of the protein family. Mol Phylogenet Evol. 2005;36:734-740.
13. Gupta A, Dong A, Lowe AW. AGR2 gene function requires a unique endoplasmic reticulum localization motif. J Biol Chem. 2012;287:4773-4782.
14. Zheng W, Rosenstiel P, Huse K, et al. Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. Genes Immun. 2006;7:11-18.
15. Kim SJ, Kim DH, Kang D, Kim JH. Expression of anterior gradient 2 is decreased with the progression of human biliary tract cancer. Tohoku J Exp Med. 2014;234:83-88.
16. Di Maro G, Salerno P, Unger K, et al. Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells. Mol Cancer. 2014;30:160.
17. Huang J, Wang L, Jiang M, et al. AGR2-mediated lung adenocarcinoma metastasis novel mechanism network through repression with interferon coupling cytoskeleton to steroid metabolism-dependent humoral immune response. Cell Immunol. 2014;290:102-106.
18. Maresh EL, Mah V, Alavi M, et al. Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer. 2010;13:680.
19. Willis S, Villalobos VM, Gevaert O, et al. Single gene prognostic biomarkers in ovarian cancer: a meta-analysis. PLoS ONE. 2016;11:e0149183.
20. Riener MO, Thiesler T, Hellerbrand C, et al. Loss of anterior gradient-2 expression is an independent prognostic factor in colorectal carcinomas. Eur J Cancer. 2014;50:1722-1730.
21. Mizuuchi Y, Aishima S, Ohuchida K, et al. Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition. Lab Invest. 2015;95:193-206.
22. Chevet E, Fessart D, Delom F, et al. Emerging roles for the oncogenic anterior gradient-2 in cancer development. Oncogene. 2013;32:2499-2509.
23. Rustin GI, Quinn M, Thigpen T, et al. Rec. new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004;96:487-488.
24. Bilyk OO, Pande NT, Buchynska LG. Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas. Exp Oncol. 2011;33:150-156.

25. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011;24:1248-1253.

26. Alvarenga AW, Coutinho-Camillo CM, Rodrigues BR, et al. A comparison between manual and automated evaluations of tissue microarray patterns of protein expression. J Histochem Cytochem. 2013;61:272-282.

27. Danks MK, Whipple DO, McPake CR, Lu D, Harris LC. Differences in epitope accessibility of p53 monoclonal antibodies suggest at least three conformations or states of protein binding of p53 protein in human tumor cell lines. Cell Death Differ. 1998;5:678-686.

28. Cole AJ, Dwight T, Gill AJ, et al. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Sci Rep. 2016;18:26191.

29. Armes JE, Davies CM, Wallace S, Taheri T, Perrin LC, Autelitano DJ. AGR2 expression in ovarian tumours: a potential biomarker for endometrioid and mucinous differentiation. Pathology. 2013;45:49-54.

30. Vanderlaag KE, Hudak S, Bald L, et al. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Breast Cancer Res. 2010;12:R32.

31. Chanda D, Lee JH, Sawant A, et al. Anterior gradient protein-2 is a regulator of cellular adhesion in prostate cancer. PLoS ONE. 2014;9:e89940.

32. Vendrell JA, Robertson KE, Ravel P, et al. A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Breast Cancer Res. 2008;10:R88.

33. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res. 2002;4:70-76.

34. Bertheau P, Lehmann-Che J, Varna M, et al. p53 in breast cancer subtypes and new insights into response to chemotherapy. Breast. 2013;22(Suppl 2):S27-S29.

35. Salmans ML, Zhao F, Andersen B. The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker. Breast Cancer Res. 2013;15:204.

36. Ondrouskova E, Sommerova L, Nenutil R, et al. AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients. Exp Mol Pathol. 2017;102:280-283.

37. Shigemasa K, Tanimoto H, Parham GP, Parmley TH, Ohama K, O’Brien TJ. Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer. J Soc Gynecol Invest. 1999;6:102-108.

38. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400-414.

39. Anttila MA, Kellokoski JK, Moisio KI, et al. Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer. Br J Cancer. 2000;82:1974-1983.

40. Rose SL, Goodheart MJ, DeYoung BR, Smith BJ, Buller RE. p21 expression predicts outcome in p53-null ovarian carcinoma. Clin Cancer Res. 2003;9:1028-1032.

41. Hu Z, Gu Y, Han B, et al. Knockdown of AGR2 induces cellular senescence in prostate cancer cells. Carcinogenesis. 2012;33:1178-1186.

42. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558-572.

43. Biliran H Jr, Wang Y, Banerjee S, et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res. 2005;11:6075-6086.

44. Noel EE, Yeste-Velasco M, Mao X, et al. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol. 2010;176:2607-2615.

45. Shi HR, Zhang RT. Expression and significance of p53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer. Ai Zheng. 2009;28:882-885.

46. Akervall J, Kurnt DM, Adams M, et al. Overexpression of cyclin D1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of the head and neck. Acta Otolaryngol. 2004;124:851-857.

47. Higa A, Mulot A, Delom F, et al. Role of pro-oncogenic protein disulfide isomerase (PDI) family member anterior gradient 2 (AGR2) in the control of endoplasmic reticulum homeostasis. J Biol Chem. 2011;286:44855-44868.

48. Sommerova L, Ondrouskova E, Vojtesek B, et al. Suppression of AGR2 in a TGF-β-induced Smad regulatory pathway mediates epithelial-mesenchymal transition. BMC Cancer. 2017;17:546.

49. Guo H, Zhu Q, Yu X, et al. Tumor-secreted anterior gradient-2 protein in breast cancer: a potential drug target for endometrioid and mucinous differentiation. PLoS ONE. 2011;286:44855-44868.

50. Sato S, Itamochi H. Ovarian cancer and drug resistance. Curr Obstet Gynecol Rep. 2015;4:18-25.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Alves MR, Cruz e Melo N, Barros-Filho MC, et al. Downregulation of AGR2, p21, and cyclin D and alterations in p53 function were associated with tumor progression and chemotherapy resistance in epithelial ovarian carcinoma. Cancer Med. 2018;7:3188–3199. https://doi.org/10.1002/cam4.1530